Soluble CD23 expression as a marker of immunomodulation and clinical response in asthma patients treated with omalizumab
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2008
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 26 Nov 2008 last checked against ClinicalTrials.gov.
- 26 Nov 2005 New trial record.